Toxicogenomics Investigation Under the eTOX Project

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Standard

Toxicogenomics Investigation Under the eTOX Project. / Taboureau, Olivier ; Hersey, Anne; Audouze, Karine Marie Laure; Gautier, Laurent; Jacobsen, Ulrik Plesner; Akhtar, Ruth; Atkinson, Francis; Overington, John P.; Brunak, Søren.

In: Journal of Pharmacogenomics & Pharmacoproteomics, 2012.

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Harvard

APA

CBE

MLA

Vancouver

Author

Taboureau, Olivier ; Hersey, Anne; Audouze, Karine Marie Laure; Gautier, Laurent; Jacobsen, Ulrik Plesner; Akhtar, Ruth; Atkinson, Francis; Overington, John P.; Brunak, Søren / Toxicogenomics Investigation Under the eTOX Project.

In: Journal of Pharmacogenomics & Pharmacoproteomics, 2012.

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Bibtex

@article{0cb22e78901343a5aa0f3a0a34483d1f,
title = "Toxicogenomics Investigation Under the eTOX Project",
publisher = "Omics Publishing Group",
author = "Olivier Taboureau and Anne Hersey and Audouze, {Karine Marie Laure} and Laurent Gautier and Jacobsen, {Ulrik Plesner} and Ruth Akhtar and Francis Atkinson and Overington, {John P.} and Søren Brunak",
year = "2012",
doi = "10.4172/2153-0645.S7-001",
journal = "Journal of Pharmacogenomics & Pharmacoproteomics",
issn = "2153-0645",

}

RIS

TY - JOUR

T1 - Toxicogenomics Investigation Under the eTOX Project

A1 - Taboureau,Olivier

A1 - Hersey,Anne

A1 - Audouze,Karine Marie Laure

A1 - Gautier,Laurent

A1 - Jacobsen,Ulrik Plesner

A1 - Akhtar,Ruth

A1 - Atkinson,Francis

A1 - Overington,John P.

A1 - Brunak,Søren

AU - Taboureau,Olivier

AU - Hersey,Anne

AU - Audouze,Karine Marie Laure

AU - Gautier,Laurent

AU - Jacobsen,Ulrik Plesner

AU - Akhtar,Ruth

AU - Atkinson,Francis

AU - Overington,John P.

AU - Brunak,Søren

PB - Omics Publishing Group

PY - 2012

Y1 - 2012

N2 - Attrition of drug candidates during pre-clinical development due to toxicity, especially hepatotoxicity and nephrotoxicity, is an important and continuing problem in the pharmaceutical industry. The reasons for this trend may be multifactorial and there is a need to improve toxicity testing paradigms within the industry. Microarray technologies have the ability to generate massive amounts of gene expression information as an initial step to decipher the molecular mechanisms of toxicologic changes, i.e. toxicogenomics. In the context of the eTOX consortium, one of public private partnership within the framework of the European Innovative Medicines Inititative (IMI), we will discuss here how the integration and analysis of toxicogenomics data can help to understanding the mechanism of toxicity<br/>of a compound and so reduce the risk of late-stage failure in pharmaceutical development.

AB - Attrition of drug candidates during pre-clinical development due to toxicity, especially hepatotoxicity and nephrotoxicity, is an important and continuing problem in the pharmaceutical industry. The reasons for this trend may be multifactorial and there is a need to improve toxicity testing paradigms within the industry. Microarray technologies have the ability to generate massive amounts of gene expression information as an initial step to decipher the molecular mechanisms of toxicologic changes, i.e. toxicogenomics. In the context of the eTOX consortium, one of public private partnership within the framework of the European Innovative Medicines Inititative (IMI), we will discuss here how the integration and analysis of toxicogenomics data can help to understanding the mechanism of toxicity<br/>of a compound and so reduce the risk of late-stage failure in pharmaceutical development.

KW - Toxicogenomics

KW - Gene expression;

KW - Drugs

KW - Rats

U2 - 10.4172/2153-0645.S7-001

DO - 10.4172/2153-0645.S7-001

JO - Journal of Pharmacogenomics & Pharmacoproteomics

JF - Journal of Pharmacogenomics & Pharmacoproteomics

SN - 2153-0645

ER -